Source:http://linkedlifedata.com/resource/pubmed/id/19842844
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2009-10-21
|
| pubmed:abstractText |
Epigenetic silencing of E-cadherin via aberrant methylation has been investigated in various human tumors, whereas evidence for elucidating mechanism underlying reduction of E-cadherin mRNA remains unclear in non-small cell lung cancer (NSCLC). The authors previously found that reduction of E-cadherin mRNA or protein expression has been frequently observed in NSCLC. In this study, the authors explore the contribution of E-cadherin methylation to the development and progression of NSCLC. The authors directly performed the bisulfite DNA sequencing to examine CpG methylation within the 5' CpG island of E-cadherin in 35 tumor and paired normal tissue specimens from patients with primary NSCLC. Then, the authors measured the level of E-cadherin mRNA by real-time quantitative polymerase chain reaction (PCR) analysis. Despite of reduction in E-cadherin mRNA by 65.7% (23/35) and presence of methylation by 28.6% (10/35) in tumors, the authors found no association of reduction of E-cadherin mRNA level with methylation of 19 sites from -181 to -9 bp located upstream from the translation start of E-cadherin in NSCLC. In conclusion, the authors provide no evidence for the presence of aberrant methylation sites of E-cadherin in tumors from patients with NSCLC, which can explain decrease of E-cadherin mRNA. Decrease in E-cadherin mRNA may be regulated by methylation-independent pathways in NSCLC.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1521-0499
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
35
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
541-53
|
| pubmed:meshHeading |
pubmed-meshheading:19842844-Aged,
pubmed-meshheading:19842844-Base Sequence,
pubmed-meshheading:19842844-Cadherins,
pubmed-meshheading:19842844-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19842844-Case-Control Studies,
pubmed-meshheading:19842844-Cell Line, Tumor,
pubmed-meshheading:19842844-CpG Islands,
pubmed-meshheading:19842844-DNA Methylation,
pubmed-meshheading:19842844-DNA Primers,
pubmed-meshheading:19842844-Female,
pubmed-meshheading:19842844-Humans,
pubmed-meshheading:19842844-Lung Neoplasms,
pubmed-meshheading:19842844-Male,
pubmed-meshheading:19842844-Middle Aged,
pubmed-meshheading:19842844-Molecular Sequence Data,
pubmed-meshheading:19842844-RNA, Messenger,
pubmed-meshheading:19842844-RNA, Neoplasm,
pubmed-meshheading:19842844-Reverse Transcriptase Polymerase Chain Reaction
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Infrequently methylated event at sites -181 to -9 within the 5' CpG island of E-cadherin in non-small cell lung cancer.
|
| pubmed:affiliation |
Laboratory of Medical Genetics, School of Basic Medicine and Biological Sciences, Medical College of Soochow University, Suzhou, PR China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|